Development of a high throughput drug screening assay to identify compounds that protect oligodendrocyte viability and differentiation under inflammatory conditions

Table 1 Confirmed cytokine protection hits from the NCC library screen

Drug class	Compound	AB screening (% quetiapine)	AB EC₅₀ (μM)	MBP EC₅₀ (μM)	Hit in OL diff^a
SERM	Raloxifene	92	0.03	0.05	•
	Toremifene	73	0.02	0.01	•
	Tamoxifen	117	0.02	0.01	•
	Mestranol	93	0.92	0.79
	Clomiphene	52	0.01	0.01
Tricyclic anti-depressants	Perphenazine	96	0.01	0.03	•
	Fluphenazine	91	0.02	0.02	•
	Prochlorperazine	110	0.04	0.04	•
	Trifluoperazine	155	0.02	0.03	•
	Quetiapine	130	0.15	0.13	•
Non-tricyclic anti-depressants	Perospirone	85	0.22	0.15	•
	Bupropion	71	3.89	3.86	•
	Bifemelane	78	0.20	0.26
	Cinanserin	64	0.97	1.59
	Trazadone	55	7.18	5.42
Muscarinic	Clemastine^c		0.14	0.14	•
	Benztropine	123	0.17	0.14	•
	Donepezil	95	0.46	0.74	•
	Vesamicol	151	1.83	2.26	•
	Oxybutynin	92	0.67	0.54	•
	Propantheline	91	2.95	1.25
Adrenergic	Salmeterol	55	0.22	0.20	•
Adrenergic	Betaxolol	52	5.56	6.21	•
Ion channel	Ifenprodil	162	0.36	0.52	•
	Benproperine	99	0.43	0.12	•
	Proxymetacaine	98	1.23	0.78	•
	DMPP	54	2.18	2.84	•
Anti-fungal	Bifonazole	105	0.44	^b	•
	Clotrimazole	171	0.77	^b
	Econazole	90	0.34	^b
Antidiabetic	Pioglitazone	56	7.34	^b
LO inhibitor	MK886	51	0.31	0.19
Histamine H1 Antagonists	Hydroxyzine Pamoate	106	0.15	0.11
Histamine H1 Antagonists	Meclizine	97	0.12	0.10
Retinoids	All-trans-retinoic acid	128	0.88	0.44
Retinoids	Acitretin	69	2.23	1.09

ISSN: 1756-0500